Pfizer Inc. $PFE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,047,094 shares of the biopharmaceutical company’s stock after selling 304,709 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Pfizer were worth $101,124,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Triad Wealth Partners LLC boosted its position in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares during the period. ETF Store Inc. boosted its stake in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC increased its position in shares of Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares during the period. Quest Investment Management LLC increased its position in shares of Pfizer by 1.3% during the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares during the period. Finally, Community Bank & Trust Waco Texas increased its position in shares of Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PFE shares. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. CICC Research started coverage on Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. Finally, Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.48.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.32 on Wednesday. Pfizer Inc. has a one year low of $21.97 and a one year high of $28.75. The stock has a fifty day moving average of $27.28 and a 200-day moving average of $26.05. The company has a market capitalization of $155.32 billion, a PE ratio of 20.08 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.